The scientist’s investigation covers issues in Internal medicine, Oncology, Breast cancer, Metastatic breast cancer and Surgery. Her research in Cancer, Chemotherapy, Phases of clinical research, Capecitabine and Lapatinib are components of Internal medicine. The various areas that Véronique Diéras examines in her Oncology study include Adverse effect, Clinical endpoint, Estrogen receptor, Toxicity and Hazard ratio.
Her study in Breast cancer is interdisciplinary in nature, drawing from both Clinical trial and Metastasis. Her Metastatic breast cancer research includes themes of Taxane, Aromatase inhibitor, Anthracycline, Vinorelbine and Bevacizumab. In Surgery, she works on issues like Gastroenterology, which are connected to Meningeal carcinomatosis, Folinic acid, Breast carcinoma and Carcinoma.
Her primary areas of study are Internal medicine, Oncology, Breast cancer, Metastatic breast cancer and Cancer. Her Internal medicine research is multidisciplinary, incorporating elements of Gastroenterology and Surgery. Her research in Oncology intersects with topics in Neutropenia, Lapatinib, Capecitabine and Docetaxel.
Her work carried out in the field of Breast cancer brings together such families of science as Regimen, Adverse effect and Hazard ratio. Her Metastatic breast cancer research focuses on Taxane and how it relates to Anthracycline. She has researched Cancer in several fields, including Gynecology and Pathology.
Her primary areas of investigation include Internal medicine, Oncology, Breast cancer, Metastatic breast cancer and Cancer. Her Internal medicine study typically links adjacent topics like Gastroenterology. Her research in the fields of Overall survival overlaps with other disciplines such as In patient.
Her study on Palbociclib is often connected to Veliparib as part of broader study in Breast cancer. Her Metastatic breast cancer research is multidisciplinary, incorporating elements of Taxane, Epidemiology, Capecitabine, Clinical endpoint and Cohort. Her Chemotherapy study incorporates themes from Trastuzumab emtansine and Subgroup analysis.
Véronique Diéras mainly investigates Internal medicine, Breast cancer, Oncology, Cancer and Metastatic breast cancer. Her Gastroenterology research extends to the thematically linked field of Internal medicine. Her work on Trastuzumab is typically connected to Veliparib as part of general Breast cancer study, connecting several disciplines of science.
The Oncology study combines topics in areas such as Carboplatin, Letrozole and Palbociclib. Within one scientific family, she focuses on topics pertaining to Biomarker under Cancer, and may sometimes address concerns connected to Immunotherapy. Her studies deal with areas such as Circulating tumor cell, Chemotherapy and Cohort as well as Metastatic breast cancer.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma;David Miles;Luca Gianni;Ian E. Krop.
The New England Journal of Medicine (2012)
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn;Miguel Martin;Hope S. Rugo;Stephen Jones.
The New England Journal of Medicine (2016)
RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
Nicholas J. Robert;Véronique Diéras;John Glaspy;Adam M. Brufsky.
Journal of Clinical Oncology (2011)
Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
Stephen Johnston;John Pippen;Xavier Pivot;Mikhail Lichinitser.
Journal of Clinical Oncology (2009)
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study
Javier Cortes;Joyce O'Shaughnessy;David Loesch;Joanne J.L. Blum.
The Lancet (2011)
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
F. Cardoso;A. Costa;E. Senkus;M. Aapro.
Annals of Oncology (2017)
Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer
Nancy U Lin;Véronique Diéras;Devchand Paul;Dominique Lossignol.
Clinical Cancer Research (2009)
Lapatinib Plus Capecitabine in Patients With Previously Untreated Brain Metastases From HER2-positive Metastatic Breast Cancer (LANDSCAPE): A Single-Group Phase 2 Study
Thomas Bachelot;Gilles Romieu;Mario Campone;Véronique Diéras.
Lancet Oncology (2013)
Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients
Joanne L. Blum;Véronique Dieras;Patricia Mucci Lo Russo;John Horton.
A New Model of Patient Tumor-Derived Breast Cancer Xenografts for Preclinical Assays
Elisabetta Marangoni;Anne Vincent-Salomon;Nathalie Auger;Armelle Degeorges.
Clinical Cancer Research (2007)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: